Lusutrombopag Safety and Dosing: Thrombosis Risk and Indications

　　1.Overview and Mechanism

　　Lusutrombopag is an oral thrombopoietin receptor agonist(TPO-RA)that stimulates TPO receptors to promote megakaryocyte production and platelet generation.It is indicated for patients with chronic liver disease-related thrombocytopenia to improve platelet counts before planned invasive procedures.

　　2.Core Safety Concern:Thrombosis Risk

　　Because the drug increases platelet production,there is a risk of thromboembolic events,especially if platelet counts rise excessively or if patients have pre-existing risk factors such as portal vein thrombosis or deep vein thrombosis.FDA labeling advises weighing risks in patients with thrombotic risk factors.The goal is not to maintain high platelet levels long-term but to provide sufficient counts for the procedure.

　　3.Common Adverse Reactions and Recognition of Serious Symptoms

　　Common side effects include headache,nausea,abdominal discomfort,fatigue,and fever,usually mild to moderate.However,persistent worsening or symptoms like chest pain,dyspnea,unilateral limb swelling/pain,or sudden dizziness require prompt medical evaluation as they may indicate thrombosis or other serious conditions.

　　4.Dosing and Monitoring

　　The US-approved regimen is 3 mg orally once daily for 7 days.Platelet counts should be assessed before starting treatment and before the procedure.Monitoring during and after therapy is essential to avoid excessive platelet elevation.

　　5.Conclusion

　　Lusutrombopag offers a valuable option for preoperative platelet enhancement in chronic liver disease,but thrombosis risk requires careful patient selection,adherence to dosing duration,and vigilance for adverse events.